View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
April 18, 2022

Sinovac to initiate trial of Omicron-specific Covid-19 vaccine in China

The Omicron-specific vaccine was found to be safe and effective in animals in preclinical research.

Sinovac Biotech has obtained approval to commence the clinical trial of its inactivated Covid-19 vaccine against the Omicron strain of the SARS-CoV-2 virus in Hong Kong, China.

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

During last year, Sinovac worked to develop Covid-19 vaccines that act on the Gamma and Delta strains of the virus. 

On 24 November last year, the Omicron variant was reported to World Health Organization (WHO), after which Sinovac obtained the strain in early December.

The company also carried out the development and preclinical research of the Omicron-specific vaccine, which showed to be safe and effective in animals.

In February this year, the company initiated the submission of clinical applications seeking approval to commence trial of the Omicron-specific Covid-19 vaccine in various countries and regions across the globe. 

The latest development marks the first clinical approval in Hong Kong for Sinovac’s Omicron-specific vaccine.

In a press statement, Sinovac said: “Sinovac will continue its extensive cooperation with global partners to promote research on its vaccine based on the original Covid-19 strain against emerging variants, as well as clinical research on sequential immunisation of new variant strain vaccines, to evaluate their safety and effectiveness.”

In July last year, the company reported data from the Phase I/II trials of its inactivated Covid-19 vaccine, CoronaVac, which showed to elicit strong immune responses in healthy children and adolescents aged three to 17 years in China.

The safety, tolerability and immunogenicity of the vaccine was assessed in the double-blind, randomised, placebo-controlled trials enrolling 552 subjects.

The trial data also demonstrated that two intramuscular doses of the vaccine given at a gap of 28 days were found to be safe and well-tolerated in the paediatric participants.

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU